Berman Howard's Form 4/A amendment
AmendedCoya Therapeutics, Inc.COYA · filed Jan 17, 2023
- Accession no.
- 0001493152-23-001702
- Filed
- Jan 17, 2023
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jan 4, 2023
This filing lists no transactions. It carries over 2 transactions from the original filing that it did not restate.
This amendment restates part of 0001493152-23-000227 (filed Jan 4, 2023). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Berman HowardCIK 0001952986 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001493152-23-000227 (filed Jan 4, 2023).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +10,000 | –F1 | – | 10,000 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +5,000 | –F1 | – | 5,000 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This Form 4/A amends the Form 4 filed by the Reporting Person on January 4, 2023 (the "Original Form 4"), which inadvertently reported the incorrect number of securities in column 5 of Table I. This Form 4/A is being filed solely to correct the number of securities reported in column 5 of Table I. No other amendments or changes have been made to the Original Form 4.
- F2
Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.